Marex Group Plc Stock Performance
| MRX Stock | 32.63 0.81 2.55% |
The company secures a Beta (Market Risk) of 0.96, which conveys possible diversification benefits within a given portfolio. Marex Group returns are very sensitive to returns on the market. As the market goes up or down, Marex Group is expected to follow. At this point, Marex Group plc has a negative expected return of -0.12%. Please make sure to verify Marex Group's treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if Marex Group plc performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Marex Group plc has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest fragile performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
| Marex Group dividend paid on 11th of September 2025 | 09/11/2025 |
| Begin Period Cash Flow | 1.5 B | |
| Total Cashflows From Investing Activities | -35.3 M |
Marex Group Relative Risk vs. Return Landscape
If you would invest 3,614 in Marex Group plc on August 26, 2025 and sell it today you would lose (351.00) from holding Marex Group plc or give up 9.71% of portfolio value over 90 days. Marex Group plc is generating negative expected returns assuming volatility of 2.7308% on return distribution over 90 days investment horizon. In other words, 24% of stocks are less volatile than Marex, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Marex Group Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Marex Group's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Marex Group plc, and traders can use it to determine the average amount a Marex Group's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0451
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | MRX |
Estimated Market Risk
| 2.73 actual daily | 24 76% of assets are more volatile |
Expected Return
| -0.12 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Marex Group is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Marex Group by adding Marex Group to a well-diversified portfolio.
Marex Group Fundamentals Growth
Marex Stock prices reflect investors' perceptions of the future prospects and financial health of Marex Group, and Marex Group fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Marex Stock performance.
| Return On Equity | 0.27 | |||
| Return On Asset | 0.0109 | |||
| Profit Margin | 0.10 % | |||
| Operating Margin | 0.14 % | |||
| Current Valuation | 3.78 B | |||
| Shares Outstanding | 71.7 M | |||
| Price To Earning | 35.06 X | |||
| Price To Book | 1.99 X | |||
| Price To Sales | 0.89 X | |||
| Revenue | 2.89 B | |||
| EBITDA | 865.8 M | |||
| Cash And Equivalents | 42.82 M | |||
| Cash Per Share | 13.47 X | |||
| Total Debt | 6.14 B | |||
| Debt To Equity | 0.72 % | |||
| Book Value Per Share | 15.09 X | |||
| Cash Flow From Operations | 1.16 B | |||
| Earnings Per Share | 3.47 X | |||
| Total Asset | 24.31 B | |||
| Retained Earnings | 722.4 M | |||
| Current Asset | 551.15 M | |||
| Current Liabilities | 574.8 M | |||
About Marex Group Performance
Evaluating Marex Group's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Marex Group has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Marex Group has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Medicis Pharmaceutical Corporationration, a specialty pharmaceutical company, engages in the development and marketing of various solutions for the treatment of dermatological and aesthetic conditions in the United States and Canada.Things to note about Marex Group plc performance evaluation
Checking the ongoing alerts about Marex Group for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Marex Group plc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Marex Group plc generated a negative expected return over the last 90 days | |
| Over 77.0% of the company shares are owned by institutional investors |
- Analyzing Marex Group's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Marex Group's stock is overvalued or undervalued compared to its peers.
- Examining Marex Group's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Marex Group's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Marex Group's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Marex Group's stock. These opinions can provide insight into Marex Group's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Marex Stock Analysis
When running Marex Group's price analysis, check to measure Marex Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marex Group is operating at the current time. Most of Marex Group's value examination focuses on studying past and present price action to predict the probability of Marex Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marex Group's price. Additionally, you may evaluate how the addition of Marex Group to your portfolios can decrease your overall portfolio volatility.